Controlled release biopolymers for enhancing the immune response

Molecular Pharmaceutics

Volumn 4, Issue 1, 2007, Pages 33-46

  Castro, Guillermo R ^a,b,c   Panilaitis, Bruce ^a   Bora, Emilia ^a   Kaplan, David L ^a  

^a Tufts University   (United States)

^b PLANTA PILOTO DE PROCESOS INDUSTRIALES MICROBIOLÓGICOS PROIMI CONICET   (Argentina)

^c INSTITUTO DE INVESTIGACIONES FISICOQUÍMICAS TEÓRICAS Y APLICADAS INIFTA   (Argentina)

Author keywords

glucan; Acinetobacter; Controlled release; Drug delivery; Emulsan; Immunopotentiation

Indexed keywords

BETA GLUCAN; BIOPOLYMER; CURDLAN; EMULSAN; MICROSPHERE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALGINATES; ANIMALS; ANTIBODY FORMATION; BETA-GLUCANS; BIOPOLYMERS; DRUG DELIVERY SYSTEMS; HUMANS; POLYSACCHARIDES, BACTERIAL;

EID: 33847237603     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp060100x     Document Type: Review

References (97)

1. Brown, G. D.; Gordon, S. Fungal β-glucans and mammalian inmunity. Immunity 2003, 19, 311-315.
2. Suda, M.; Ohno, N.; Hashimoto, T.; Koizumi, K.; Adachi, Y.; Yadomae, T. Kupffer cells play important roles in the metabolic degradation of a soluble anti-tumor (1→3)-β-D-glucan, SSG, in mice. FEMS Immunol. Med. Microbiol. 1996, 15, 93-100.
3. Motoi, M.; Ishibashi, K.; Mizukamio, O.; Miura, N. N.; Adachi, Y.; Ohno, N. Anti β-glucan antibody in cancer patients. Int. J. Med. Mushrooms 2004, 6, 41-48.
4. Chourasia, M. K.; Jain, S. K. Polysaccharides for colon targeted drug delivery. Drug Delivery 2004, 11, 129-148.
5. Gutnick, D. L.; Shabtai, Y. Exopolysaccharide bioemulsifiers in biosurfactants and biotechnology. In Exopolysaccharide Bioemulsifiers; Kosaric, N., Cairns, W. L., Gray, C. C., Eds.; Marcel Dekker, Inc.: New York, 1987; Vol. 25, pp 211-246.
6. Gutnick, D. L.; Shabtai, Y. Exopolysaccharide bioemulsifiers in biosurfactants and biotechnology. In Exopolysaccharide Bioemulsifiers; Kosaric, N., Cairns, W. L., Gray, C. C., Eds.; Marcel Dekker, Inc.: New York, 1987; Vol. 25, p 232.
7. Belsky, I.; Gutnick, D. L.; Rosenberg, E. Emulsifier of Arthrobacter RAG-1: Determination of emulsifier-bound fatty acids. FEBS Lett. 1979, 101, 175-178.
8. Gorkovenko, A.; Zhang, J.; Gross, R. A.; Allen, A. L.; Kaplan, D. L. Bioengineering of emulsifier structure: Emulsan variants. Can. J. Microbiol. 1997, 43, 384-390.
9. Lerouge, I.; Vanderleyden, J. O-Antigen structural variation: Mechanisms and possible roles in animal/plant-microbe interactions. FEMS Microbiol. Rev. 2002, 26, 17-47.
10. Panilaitis, B.; Johri, A.; Blank, W.; Kaplan, D. L.; Fuhrman, J. A. Adjuvant activity of emulsan, a secreted lipopolysaccharide from Acinetobacter venetianus. Clin. Diagn. Lab. Immunol. 2002, 9, 1240-1247.
11. Sinha, V. R.; Trehan, A. Biodegradable microspheres for protein delivery. J. Controlled Release 2003, 90, 261-280.
12. Haupt, S.; Rubinstein, A. The colon as a possible target for orally administered peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19, 499-551.
13. Bernkop-Schnürch, A.; Kirchmayer, R.; Kratzel, M. Synthesis, development and in vitro evaluation of drug delivery systems with protective effect against degradation by pepsin, J. Drug Targeting 1999, 7, 55-63.
14. Alban, S.; Franz, G. Characterization of the anticoagulant actions of a semisynthetic curdlan sulfate. Thromb. Res. 2000, 99, 377-388.
15. Lee, K. B.; Bae, J. H.; Kim, J. S.; Yoo, Y. C.; Kim, B. S.; Kwak, S. T.; Kim, Y. S. Anticogaulant activity of sulfoalkyl derivatives of curdlan. Arch. Pharm. Res. 2001, 24, 109-113.
16. Jenkins, D. J. A.; Kendall, C. W. C.; Vuksan, V.; Vidgen, E.; Parker, T.; Faulkner, D.; Mehling, C. C.; Garsetti, M.; Testolin, G.; Cunnane, S. C.; Ryan, M. A.; Corey, P. N. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: Serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am. J. Clin. Nutr. 2002, 75, 834-839.
17. Wursch, P.; Pi-Sunyer, F. X. The role of viscous soluble fiber in the metabolic control of diabetes: A review with special emphasis on cereals rich in β-glucan. Diabetes Care 1997, 20, 1774-1780.
18. Ross, G. D.; Větvička, V.; Yan, J.; Xia, Y.; Větvičková, J. Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology 1999, 42, 61-74.
19. Tzianabos, A. O. Polysaccharide immunomodulators as therapeutic agents: Structural aspects and biologic function. Clin. Microbiol. Rev. 2000, 13, 523-533.
20. Havlik, I.; Looareesuwan, S.; Vannaphan, S.; Wilairatana, P.; Krudsood, S.; Thuma, P. E.; Kozbor, D.; Watanabe, N.; Kaneko, Y. Curdlan sulfate in human severe/cerebral Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2005, 99, 333-340.
21. Igarashi, I.; Kimani Njonge, F.; Kaneko, Y.; Nakamura, Y. Babesia bigemina: In vitro and in vivo effects of curdlan sulfate on growth of parasites. Exp. Parasitol. 1998, 90, 290-293.
22. Yun, C.-H.; Estrada, A.; Van Kessel, A.; Park, B.-C.; Laarveld, B. β-Glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections. FEMS Immunol. Med. Microbiol. 2003, 35, 67-75.
23. Yoshida, T.; Kruger, R.; Inglis, V. Augmentation of non-specific protection in African catfish, Clarias gariepinus (Burchell) by the long-term oral administration of immunostimulants. J. Fish Dis. 1995, 18, 195-198.
24. Robertsen, B.; Rorstad, G.; Engstad, R. E.; Raa, J. Enhancement of non-specific disease resistance in Atlantic salmon Salmo salar L. by a glucan from Saccharomyces cerevisiae cell wall. J. Fish Dis. 1990, 13, 391-400.
25. Siwicki, A. K.; Anderson, D. P.; Rumsey, G. L. Dietary intake of immunostimulants by rainbow trout affects non-specific immunity and protection against furunculosis. Vet. Immunol. Immunopathol. 1994, 41, 125-139.
26. Yano, T.; Matsuyama, H.; Mangindaan, R. E. P. Polysaccharide-induced protection of carp Cyprinus carpio L. against bacterial infection. J. Fish Dis. 1991, 14, 577-582.
27. Jeney, G.; Anderson, D. P. Glucan injection or bath exposures given alone or in combination with bacterin enhance the non-specific defense mechanisms in rainbow trout (Oncorhynchus mykiss). Aquaculture 1993, 116, 315-329.
28. Matsuyama, H.; Mangindaan, R. E. P.; Yano, T. Protective effect of Schizophyllan and Scleroglucan against Streptococcus sp. Infection in yellowtail (Seriola quinqueradiata). Aquaculture 1992, 101, 197-203.
29. Chen, D.; Ainsworth, A. J. Glucan administration potentiates immune defense mechanisms of channel catfish, Ictalurus punctatus Rafinesque. J. Fish Dis. 1992, 15, 295-304.
30. Jorgensen, J. B.; Robertsen, B. Yeast β-glucan stimulates respiratory burst activity of Atlantic salmon (Salmo salar L.) macrophages. Dev. Comp. Immunol. 1995, 19, 43-57.
31. Engstad, R. E.; Robertsen, B.; Frivold, E. Yeast glucan induces increase in activity of lysozyme and complement-mediated hemolytic activity in Atlantic salmon blood. Fish Shellfish Immunol. 1992, 2, 287-297.
32. Fujiki, K.; Shin, D. H.; Nakao, M.; Yano, T. Molecular cloning and expression analysis of carp (Cyprinus carpio) interleukin-1b, high affinity immunoglobulin E FC receptor g subunit and serum amyloid A. Fish Shellfish Immunol. 2000, 10, 229-242.
33. Solem, S. T.; Jorgensen, J. B.; Robertsen, B. Stimulation of respiratory burst and phagocytic activity in Atlantic salmon (Salmo salar L.) macrophages by lipopolysaccharide. Fish Shellfish Immunol. 1995, 5, 475-491.
34. Saeed, M. O.; Plumb, J. A. Immune response of channel catfish to lipopolysaccharide and whole cell Edwardsiella ictaluri vaccines. Dis. Aquat. Org. 1986, 2, 21-25.
35. Zhang, M. X.; Brandhorst, T. T.; Kozel, T. R.; Klein, B. S. Role of glucan and surface protein BAD 1 in complement activation by Blastomyces dermatitidis yeast. Infect. Immun. 2001, 69, 7559-7564.
36. Torosantucci, A.; Bromuro, C.; Chiang, P.; De Bernardis, F.; Berti, F.; Galli, C.; Norelli, F.; Bellucci, C.; Polonelli, L.; Costantino, P.; Rappuoli, R.; Cassone, A. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 2005, 202, 597-606.
37. Ishibashi, K. M.; Yoshida, I.; Nakabayashi, H.; Shinohara, N. N.; Miura, Y.; Adachi Ohno, N. Role of anti-β-glucan antibody in host defense against fungi. FEMS Immunol. Med. Microbiol. 2005, 44, 99-109.
38. Casadevall, A.; Dadachova, E.; Pirofski, L. A. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2004, 2, 695-703.
39. Xiao, Z.; Trincado, C. A.; Murtaugh, M. P. β-Glucan enhancement of T cell IFNγ response in swine. Vet. Immunol. Immunopathol. 2004, 102, 315-320.
40. van Burik, J. A.; Magee, P. T. Aspects of fungal pathogenesis in humans. Annu. Rev. Microbiol. 2001, 55, 743-772.
41. Yoshida, T.; Yasuda, Y.; Mimura, T.; Kaneko, Y.; Nakashima, H.; Yamamoto, N.; Urdu, T. Synthesis of curdlan sulfates having inhibitory effects in vitro against AIDS viruses HIV-1 and HIV-2. Carbohydr. Res. 1995, 276, 425-436.
42. Naito, T.; Okada, M.; Ogasawara, H.; Kaneko, H.; Hishikawa, T.; Matsumoto, T.; Sekigawa, I.; Hashimoto, H.; Kaneko, Y. Curdlan sulfate induces the downmodulation of chemokine receptors leading to suppression of HIV infection. J. Acquired Immune Defic. Syndr. 2001, 26, 512-513.
43. Thornton, B. P.; Vetvicka, V.; Pitman, N.; Goldman, R. C.; Ross, G. D. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 1996, 156, 1235-1246.
44. Xia, Y.; Ross, G. D. Generation of recombinant fragments of CD11b expressing the functional β-glucan-binding lectin site of CR3 (CD11b/CD18). J. Immunol. 1999, 162, 7285-7293.
45. Shimizu, J.; Kudoh, K.; Wada, M.; Takita, T.; Innami, S.; Maekawa, A.; Tadokoro, M. Dietary curdlan suppresses dimethylhydrazine-induced aberrant crypt foci formation in Sprague-Dawley rat. Nutr. Res. 2002, 22, 867-877.
46. Kiho, T.; Matsushita, M.; Usui, S.; Ukai, S. Biological activities of (1-3)-β-D-glucans with reducing glucose side chains. Biosci., Biotechnol., Biochem. 1998, 62, 570-572.
47. Usui, S.; Matsunaga, T.; Ukai, S.; Kiho, T.; Hirano, K. Growth suppressing factor for endothelial cells exhibits tumor regressing activity. Biol. Pharm. Bull. 1999, 22, 353-359.
48. Cheung, N. K.; Modak, S. Oral (133),(134)-β-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. 2002, 8, 1217-1223.
49. Cheung, N. K.; Modak, S.; Vickers, A.; Knuckles, B. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. 2002, 51, 557-564.
50. Vetvicka, V.; Terayama, K.; Mandeville, R.; Brousseau, P.; Kournikakis, B.; Ostroff, G. Pilot study: Orally-administered yeast β-1,3-glucan prophylactically protects against anthrax infection and cancer in mice. JANA 2002, 5, 1-5.
51. Hong, F.; Hansen, R. D.; Yan, J.; Allendorf, D. J.; Baran, J. T.; Ostroff, G. R.; Ross, G. D. β-Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 2003, 63, 9023-9031.
52. Sier, C. F. M.; Gelderman, K. A.; Prins, F. A.; Gorter, A. β-Glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int. J. Cancer 2004, 109, 900-908.
53. Chatterjee, S. Lactosylceramide stimulates aortic smooth muscle cell proliferation. Biochem. Biophys. Res. Commun. 1991, 181, 554-561.
54. Zimmerman, J. W.; Lindermuth, J.; Fish, P. A.; Palace, G. P.; Stevenson, T. T.; DeMong, D. E. A novel carbohydrate-glycosphingolipid interaction between a β-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J. Biol. Chem. 1998, 273, 22014-22020.
55. Wakshull, E.; Brunke-Reese, D.; Lindermuth, J.; Fisette, L.; Nathans, R. S.; Crowley, J. J.; Tufts, J. C.; Zimmerman, J.; Mackin, W.; Adams, D. S. PGG-Glucan, a soluble β-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-κB-like factor in human PMN: Evidence for a glycosphingolipid β-(1,3)-glucan receptor. Immunopharmacology 1999, 41, 89-107.
56. Hahn, P. Y.; Evans, S. E.; Kottom, T. J.; Standing, J. E.; Pagano, R. E.; Limper, A. H. Pneumocystis carinii cell wall β-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J. Biol. Chem. 2003, 278, 2043-2050.
57. Gong, N.; Wei, H.; Chowdhury, H. S.; Chatterjee, S. Lactosylceramide recruits PKC α/ε and phospholipase A2 to stimulate PECAM-1 expression and adhesion of human monocytes to endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6490-6495.
58. Dushkin, M. I.; Safina, A. F.; Vereschagin, E. I.; Schwartz, Y. S. Carboxymethylated β-1,3-glucan inhibits the binding and degradation of acetylated low density lipoproteins in macrophages in vitro and modulates their plasma clearance in vivo. Cell Biochem. Funct. 1996, 14, 209-217.
59. Vereschagin, E. I.; Van Lambalgen, A. A.; Dushkin, M. I.; Schwartz, Y. S.; Polyakov, L.; Heemskerk, A.; Huisman, E.; Thijs, L. G.; Van den Bos, G. C. Soluble glucan protects against endotoxin shock in the rat: The role of the scavenger receptor. Shock 1998, 9, 193-198.
60. Rice, P. J.; Kelley, J. L.; Kogan, G.; Ensley, H. E.; Kalbfleisch, J. H.; Browder, I. W.; Williams, D. L. Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-β-D-glucans. J. Leukocyte Biol. 2002, 72, 140-146.
61. Lemaitre, B.; Nicolas, E.; Michaut, L.; Reichhart, J. M.; Hoffmann, J. A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86, 973-983.
62. Takeda, K.; Akira, S. TLR signaling pathways. Semin. Immunol. 2004, 16, 3-9.
63. Sutmuller, R. P. M.; Morgan, M. E.; Netea, M. G.; Grauer, O.; Adema, G. J. Toll-like receptors on regulatory T cells: Expanding immune regulation. Trends Immunol. 2006, in press.
64. Young, S. H.; Ye, J.; Frazer, D. G.; Shi, X.; Castranova, V. Molecular mechanism for tumor necrosis factor-α production in 1→3-β-glucan (zymosan)-activated macrophages. J. Biol. Chem. 2001, 276, 20781-20787.
65. Gantner, B. N.; Simmons, R. M.; Canavera, S. J.; Akira, S.; Underhill, D. M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 2003, 197, 1107-1117.
66. Willment, J. A.; Gordon, S.; Brown, G. D. Characterisation of the human β-glucan receptor and its alternatively spliced isoforms. J. Biol. Chem. 2001, 276, 43818-43823.
67. Ariizumi, K.; Shen, G. L.; Shikano, S.; Xu, S.; Ritter, R., III; Kumamoto, T.; Edelbaum, D.; Morita, A.; Bergstresser, P. R.; Takashima, A. Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. J. Biol. Chem. 2000, 275, 20157-20167.
68. Taylor, P. R.; Brown, G. D.; Reid, D. M.; Willment, J. A.; Martinez-Pomares, L.; Gordon, S.; Wong, S. Y. C. The β-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol. 2002, 169, 3876-3882.
69. Brown, G. D. Dectin-1: A signalling non-TLR pattern-recognition receptor. Nat. Rev. Immunol. 2006, 6, 33-43.
70. Gorkovenko, A.; Zhang, J.; Gross, R. A.; Allen, A. L.; Ball, D.; Kaplan, D. L. Biosynthesis of emulsan variants: Direct incorporation of exogenous fatty acids. Proc. Am. Chem. Soc., Div. Polym. Sci. Eng. 1995, 72, 92-93.
71. Gorkovenko, A.; Zhang, J.; Gross, R.; Kaplan, D. L.; Allen, A. L. Control of unsaturated fatty acid substituents in emulsans. Carbohydr. Polym. 1999, 39, 79-84.
72. Zhang, J.; Gorkovenko, A.; Gross, R. A.; Allen, A. L.; Kaplan, D. L. Incorporation of 2-hydroxyl fatty acids by Acinetobacter venetianus RAG-1 to tailor emulsan structure. Int. J. Biol. Macromol. 1997, 20, 9-21.
73. Johri, A. K.; Blank, W.; Kaplan, D. L. Bioengineered emulsans from Acientobacteer venetianus RAG-1 transposon mutants. Appl. Microbiol. Biotechnol. 2002, 59, 217-223.
74. Herrero, M.; Lorenzo, V.; Timmis, K. N. Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in Gram-negative bacteria. J. Bacteriol. 1990, 172, 6557-6567.
75. Leahy, J. G.; Jones-Meehan, J. M.; Colwell, R. R. Transformation of Acinetobacter venetianus RAG-1 by electroporation. Can. J. Microbiol. 1993, 40, 233-236.
76. Leahy, J. G.; Jones-Meehan, J. M.; Pullias, E. L.; Colwell, R. R. Transposon mutagenesis in Acinetobacter venetianus RAG-1. J. Bacteriol. 1993, 175, 1838-1840.
77. Johri, A. K.; Yalpani, M.; Kaplan, D. L. Incorporation of fluorinated fatty acid esters into emulsan by Acinetobacter calcoaceticus RAG-1. Biochem. Eng. J. 2003, 16, 175-181.
78. Nishimura, K.; Ishihara, C.; Ukei, S.; Tokura, S.; Azuma, I. Stimulation of cytokine production in mice using deacetylated chitin. Vaccine 1986, 4, 151-156.
79. Nishimura, K.; Nishimura, S.; Seo, H.; Nishi, N.; Tokura, S.; Azuma, I. Macrophage activation with multi-porous beads prepared from partially deacetylated chitin. J. Biomed. Mater. Res. 1986, 20, 1359-1372.
80. Nishimura, K.; Nishimura, S.; Seo, H.; Nishi, N.; Tokura, S.; Azuma, I. Effect of multiporous microspheres derived from chitin and partially deacetylated chitin on the activation of mouse peritoneal macrophages. Vaccine 1987, 5, 136-140.
81. Shibata, Y.; Foster, L. A.; Metzger, W. J.; Myrvik, Q. N. Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice. Infect. Immun. 1997, 65, 1734-1741.
82. Isaka, M.; Yasuda, Y.; Taniguchi, T.; Kozuka, S.; Matano, K.; Maeyama, J.; Morokuma, K.; Ohkuma, K.; Goto, N.; Tochikubo, K. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 2003, 21 (11-12), 1165-1173.
83. Sepulveda-Amor, J.; Valdespino-Gomez, J. L.; Garcia-Garcia, Mde. L.; Bennett, J.; Islas-Romero, R.; Echaniz-Aviles, G.; de Castro, J. F. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002, 20, 2790-2795.
84. Coulter, A.; Harris, R.; Davis, R.; Drane, D.; Cox, J.; Ryan, D.; Sutton, P.; Rockman, S.; Pearse, M. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 2003, 21 (9-10), 946-949.
85. Dilraj, A.; Cutts, F. T.; de Castro, J. F.; Wheeler, J. G.; Brown, D.; Roth, C.; Coovadia, H. M.; Bennett, J. V. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: A randomised trial. Lancet 2000, 355 (9206), 798-803.
86. Storer, J. B. Longevity and gross pathology at death in 22 inbred strains of mice. J. Gerontol. 1966, 21, 404-409.
87. Lehne, G.; Haneberg, B.; Gaustad, P.; Johansen, P. W.; Preus, H.; Abrahamsen, T. G. Oral administration of a new soluble branched β-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. Clin. Exp. Immunol. 2005, 143, 65-69.
88. Okazaki, M.; Adachi, Y.; Ohno, N.; Yadomae, T. Structure-activity relationship of (1→3)-β-D-glucans in the induction of cytokine production from macrophages, in vitro. Biol. Pharm. Bull. 1995, 18, 1320-1327.
89. Ishibashi, K.; Miura, N. N.; Adachi, Y.; Ohno, N.; Yadomae, T. Relationship between solubility of grifolan, a fungal 1,3-β-D- glucan, and production of tumor necrosis factor by macrophages in vitro. Biosci., Biotechnol., Biochem. 2001, 65, 1993-2000.
90. Na, K.; Park, K.-H.; Kim, S. W.; Bae, Y. H. Self assembled hydrogel nanoparticles from curdlan derivatives: Characterization, anticancer drug release and interaction with a hepatoma cell line (HepG2). J. Controlled Release 2000, 69, 225-236.
91. Dobashi, T.; Yoshihara, H.; Nobe, M.; Koike, M. Liquid crystalline gel beads of curdlan, Langmuir 2005, 21, 2-4.
92. Peppas, N. A. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 2000, 50, 27-46.
93. Lee, K. Y.; Mooney, D. J. Hydrogels for tissue engineering. Chem. Rev. 2001, 101, 1869-1880.
94. Dornish, M.; Kaplan, D.; Skaugrud, Ø. Standards and guidelines for biopolymers in tissue-engineered medical products ASTM alginate and chitosan standard guides. Ann. N.Y. Acad. Sci. 2001, 944, 388-397.
95. Gombotz, W. R.; Wee, S. F. Protein release from alginate matrices. Adv. Drug Delivery Rev. 1998, 31, 267-285.
96. Castro, G. R.; Kamdar, R.; Panilaitis, B.; Kaplan, D. L. Protein release from emulsan coated microspheres. J. Controlled Release 2005, 109, 149-157.
97. Castro, G. R.; Bora, E.; Panilaitis, B.; Kaplan, D. L. Emulsan coated alginate microspheres, a new biodegradable system for drug delivery. In Degradable Polymers and Materials; Khemani, K., Scholz, C., Eds.; Oxford University Press: Washington, DC, 2006; pp 14-29.